Stay updated with breaking news from Ultimovacs asa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, demonstrated a clinically meaningful overall. ....
The results from the NIPU study will be presented by the Principal Investigator as an oral presentation at the ESMO Congress 2023 in Madrid, Spain, 20-24. ....
Oslo, May 10, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces. ....
Oslo, 16 November 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital, related to the. ....